JPH027572B2 - - Google Patents

Info

Publication number
JPH027572B2
JPH027572B2 JP59026179A JP2617984A JPH027572B2 JP H027572 B2 JPH027572 B2 JP H027572B2 JP 59026179 A JP59026179 A JP 59026179A JP 2617984 A JP2617984 A JP 2617984A JP H027572 B2 JPH027572 B2 JP H027572B2
Authority
JP
Japan
Prior art keywords
carnitine
coenzyme
animals
rats
treated
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
JP59026179A
Other languages
English (en)
Japanese (ja)
Other versions
JPS59186914A (ja
Inventor
Beruterii Aruberuto
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sigma Tau Industrie Farmaceutiche Riunite SpA
Original Assignee
Sigma Tau Industrie Farmaceutiche Riunite SpA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sigma Tau Industrie Farmaceutiche Riunite SpA filed Critical Sigma Tau Industrie Farmaceutiche Riunite SpA
Publication of JPS59186914A publication Critical patent/JPS59186914A/ja
Publication of JPH027572B2 publication Critical patent/JPH027572B2/ja
Granted legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/205—Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
JP59026179A 1983-02-16 1984-02-16 心臓及び血管系の治療に使用するための代謝及びエネルギ−活性を有する医薬組成物 Granted JPS59186914A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CH858/831 1983-02-16
CH858/83A CH655005A5 (it) 1983-02-16 1983-02-16 Composizione farmaceutica ad azione metabolica ed energetica utilizzabile in terapia cardiaca e vascolare.

Publications (2)

Publication Number Publication Date
JPS59186914A JPS59186914A (ja) 1984-10-23
JPH027572B2 true JPH027572B2 (index.php) 1990-02-19

Family

ID=4196830

Family Applications (1)

Application Number Title Priority Date Filing Date
JP59026179A Granted JPS59186914A (ja) 1983-02-16 1984-02-16 心臓及び血管系の治療に使用するための代謝及びエネルギ−活性を有する医薬組成物

Country Status (11)

Country Link
US (1) US4599232A (index.php)
JP (1) JPS59186914A (index.php)
BE (1) BE898918A (index.php)
CH (1) CH655005A5 (index.php)
DE (1) DE3405581A1 (index.php)
DK (1) DK165167C (index.php)
FR (1) FR2543827B1 (index.php)
GB (1) GB2137088B (index.php)
IT (1) IT1170235B (index.php)
NL (1) NL192778C (index.php)
SE (1) SE457143B (index.php)

Families Citing this family (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1209519B (it) * 1984-04-10 1989-08-30 Poli Ind Chimica Spa Composti ad attivita'cardiotrofica.
CH662505A5 (it) * 1985-04-30 1987-10-15 Seuref Ag Composizioni farmaceutiche ad azione protettiva vascolare.
CH670763A5 (index.php) * 1985-08-02 1989-07-14 Seuref Ag
CH666183A5 (it) * 1985-08-06 1988-07-15 Seuref Ag Composizione farmaceutica ad azione protettiva cardiaca e metabolica sul metabolismo energetico muscolare.
IT1184655B (it) * 1985-10-14 1987-10-28 Sigma Tau Ind Farmaceuti Imiego di acetil l-carnitina nel trattamento terapeutico degli stati di shock
SE8703321D0 (sv) * 1987-08-27 1987-08-27 Sockerbolaget Ab Kostforsterkning
JPH02188523A (ja) * 1989-01-13 1990-07-24 M S C:Kk 睡眠時無呼吸症治療薬
GB8907276D0 (en) * 1989-03-31 1989-05-17 Therapy Advisory Services Limi Health supplement
AT393954B (de) * 1990-02-28 1992-01-10 Bock Orthopaed Ind Verfahren und vorrichtung zur bestimmung von gebrauchseigenschaften eines prothesenschaftes
IT1254314B (it) * 1992-03-27 1995-09-14 Sigma Tau Ind Farmaceuti Composizioni farmaceutiche conyenenti l-carnitina e acil- carnitine inassociazione con ace-inibitori per il trattamento di patologie cardiovascolari.
ES2224098T3 (es) * 1992-05-28 2005-03-01 Centre For Molecular Biology And Medicine, Derivados de quinona para aumentar la bioenergia celular.
DE4335454A1 (de) * 1993-10-19 1995-04-20 Schleicher Peter Geriatrikum
US5707971A (en) * 1995-06-07 1998-01-13 Life Resuscitation Technologies, Inc. Modulation of glycolytic ATP production
US6080788A (en) * 1997-03-27 2000-06-27 Sole; Michael J. Composition for improvement of cellular nutrition and mitochondrial energetics
BR9808088A (pt) * 1997-03-27 2000-03-08 Michael J Sole Suplemento nutricional, uso do mesmo e métodos de tratamento de um sistema orgânico crìtico e de insuficiência cardìaca congestiva
IT1291127B1 (it) * 1997-04-01 1998-12-29 Sigma Tau Ind Farmaceuti Integratore alimentare per soggetti dediti ad intensa e prolungata attivita' fisica
US5889055A (en) * 1997-04-04 1999-03-30 Howard; James R. L-carnitine and acetyl-L-carnitine combined for prevention and treatment of syndromes related to diseases of energy metabolism
US5973004A (en) * 1997-04-04 1999-10-26 Howard; James R. L-carnitine, acetyl-L-carnitine, and pantothenic acid or ubiquinone, combined for prevention and treatment of syndromes related to ineffective energy metabolism
US5916912A (en) * 1997-06-16 1999-06-29 The Regents Of The University Of California Dietary composition for enhancing metabolism and alleviating oxidative stress
US20050196470A9 (en) * 1998-04-03 2005-09-08 Wuh Hank C Method and composition for enhancing sexual desire
US7371415B1 (en) 1998-04-03 2008-05-13 The Daily Wellness Company Method and composition for improving sexual fitness
WO1999051252A1 (en) 1998-04-03 1999-10-14 The Daily Wellness Company Compositions comprising l-arginine, ginseng and gingko biloba for enhancing blood circulation
IT1299266B1 (it) * 1998-05-15 2000-02-29 Sigma Tau Ind Farmaceuti Inibitori reversibili della carnitina palmitoil trasferasi
US6616942B1 (en) 1999-03-29 2003-09-09 Soft Gel Technologies, Inc. Coenzyme Q10 formulation and process methodology for soft gel capsules manufacturing
WO2001021208A1 (en) 1999-09-23 2001-03-29 Juvenon Corporation Nutritional supplement for increased energy and stamina
US6562869B1 (en) 1999-09-23 2003-05-13 Juvenon, Inc. Nutritional supplement for increased energy and stamina
US20070072927A1 (en) * 1999-09-23 2007-03-29 Vita Joseph A Nutritional supplement for increased energy and stamina
JP2003513039A (ja) 1999-11-03 2003-04-08 ジュヴェノン インコーポレイテッド 良性の健忘症を治療する方法
US6740338B1 (en) 2000-01-20 2004-05-25 Raj K. Chopra Reduced form of Cenzyme Q in high bioavailability stable oral dosage form
US8753675B1 (en) 2000-01-20 2014-06-17 Raj K. Chopra Reduced form of Coenzyme Q in high bioavailability stable dosage forms and related applications
JP2003529347A (ja) * 2000-01-25 2003-10-07 ジュヴェノン インコーポレイテッド 高齢ペット用の栄養補給食品
DE10036798A1 (de) * 2000-07-28 2002-02-07 Beiersdorf Ag Mittel zur Behandlung der Haare und der Kopfhaut
US6441050B1 (en) 2000-08-29 2002-08-27 Raj K. Chopra Palatable oral coenzyme Q liquid
US6497885B2 (en) 2000-12-22 2002-12-24 The Daily Wellness Company Method and composition for improving fertility health in female and male animals and humans
US6989164B2 (en) 2000-12-22 2006-01-24 The Daily Wellness Company Method and composition for improving male fertility health
US20060062864A1 (en) * 2000-12-28 2006-03-23 Mccleary Edward L Weight loss composition and method
US6579866B2 (en) 2000-12-28 2003-06-17 Mccleary Larry Composition and method for modulating nutrient partitioning
US20040043013A1 (en) 2000-12-28 2004-03-04 Mccleary Edward Larry Metabolic uncoupling therapy
KR100685696B1 (ko) * 2001-05-10 2007-02-23 카네카 코포레이션 활성 성분으로 조효소 ｑ를 함유하는 경점막 투여용 조성물
WO2003002147A1 (en) * 2001-06-28 2003-01-09 Takeda Chemical Industries, Ltd. Preventives/remedies for organ functional disorders and organ dysfunction
US8703209B2 (en) * 2003-06-17 2014-04-22 Edward Larry McCleary Composition and method for modulating hydrogen ion physiology
AU2004257756A1 (en) * 2003-07-10 2005-01-27 Carl A. Forest Foods, beverages, condiments, spices and salad dressings with specialized supplements
US20080089877A1 (en) * 2003-08-14 2008-04-17 Udell Ronald G Super Absorption Coenzyme Q10
US7169385B2 (en) * 2003-09-29 2007-01-30 Ronald G. Udell Solubilized CoQ-10 and carnitine
AU2004277951B2 (en) 2003-09-29 2010-11-11 Soft Gel Technologies, Inc. Solubilized CoQ-10
US8124072B2 (en) 2003-09-29 2012-02-28 Soft Gel Technologies, Inc. Solubilized CoQ-10
US20050232911A1 (en) * 2004-04-19 2005-10-20 Schreiber Brian D Prevention and treatment of metabolic abnormalities associated with excess intramyocellular lipid
WO2006012267A1 (en) * 2004-06-29 2006-02-02 Elixirin Corporation Dietary compositions for enhancing metabolism and reducing reactive oxygen species
EP2471530B1 (en) 2005-06-01 2017-01-11 Edison Pharmaceuticals, Inc. Redox-active therapeutics for treatment of mitochondrial diseases and other conditions and modulation of energy biomarkers
US20050249803A1 (en) * 2005-06-03 2005-11-10 Udell Ronald G Soft gel capsules containing polymethoxylated flavones and palm oil tocotrienols
US7887852B2 (en) * 2005-06-03 2011-02-15 Soft Gel Technologies, Inc. Soft gel capsules containing polymethoxylated flavones and palm oil tocotrienols
ES2823728T3 (es) * 2005-09-15 2021-05-10 Ptc Therapeutics Inc Variantes de cola de agentes terapéuticos con actividad redox para el tratamiento de enfermedades mitocondriales y otras afecciones y la modulación de biomarcadores de energía
US20100022629A1 (en) * 2006-01-13 2010-01-28 Elixirin Dietary Methods and Compositions for Enhancing Metabolism and Reducing Reactive Oxygen Species
US9278085B2 (en) 2006-02-22 2016-03-08 Edison Pharmaceuticals, Inc. Side-chain variants of redox-active therapeutics for treatment of mitochondrial diseases and other conditions and modulation of energy biomarkers
US20080020022A1 (en) * 2006-06-05 2008-01-24 Udell Ronald G Chewable co-enzyme q-10 capsule
JP2009037201A (ja) * 2007-03-14 2009-02-19 Fujifilm Corp 感光性樹脂組成物、それを用いた硬化レリーフパターンの製造方法及び半導体装置
US8343541B2 (en) 2007-03-15 2013-01-01 Soft Gel Technologies, Inc. Ubiquinol and alpha lipoic acid compositions
ES2306610B1 (es) * 2007-04-16 2009-09-11 Universidad De Sevilla Uso de la l-carnitina para el tratamiento de la hipertension arterial.
JP5343002B2 (ja) * 2007-06-22 2013-11-13 株式会社カネカ 生理活性物質含有組成物
WO2009001787A1 (ja) * 2007-06-22 2008-12-31 Kaneka Corporation 補酵素ｑ１０含有組成物
EP2186789B1 (en) * 2007-08-22 2013-12-25 Kaneka Corporation Method of producing reduced coenzyme q10 and method of stabilizing the same
EP2255818B1 (en) * 2008-02-19 2018-08-22 Earnest Medicine Co., Ltd. Oral or enteral composition useful for recovery of physical functions
LT3827815T (lt) 2008-09-10 2023-10-10 Ptc Therapeutics, Inc. Psichologinių raidos sutrikimų gydymas oksidacijos redukcijos atžvilgiu aktyviais vaistais
US10703701B2 (en) 2015-12-17 2020-07-07 Ptc Therapeutics, Inc. Fluoroalkyl, fluoroalkoxy, phenoxy, heteroaryloxy, alkoxy, and amine 1,4-benzoquinone derivatives for treatment of oxidative stress disorders

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2903558C2 (de) * 1978-02-03 1994-09-01 Sigma Tau Ind Farmaceuti Verwendung von L-Carnitin
IT1206954B (it) * 1979-02-12 1989-05-17 Sigma Tau Ind Farmaceuti Agenti terapeutici a base di un acil derivato della carnitina per la cura di vasculopatie periferiche
US4346107A (en) * 1979-02-12 1982-08-24 Claudio Cavazza Pharmaceutical composition comprising acyl-carnitine for the treatment of impaired cerebral metabolism
IT1142934B (it) * 1981-11-06 1986-10-15 Sigma Tau Ind Farmaceuti Uso della carnitina e delle acilcarnitine inferiori nel trattamento terapeutico della patologia delle vene

Also Published As

Publication number Publication date
JPS59186914A (ja) 1984-10-23
NL192778B (nl) 1997-10-01
SE8400851D0 (sv) 1984-02-16
GB8403668D0 (en) 1984-03-14
DK165167B (da) 1992-10-19
DK72284D0 (da) 1984-02-16
FR2543827A1 (fr) 1984-10-12
IT8323559A0 (it) 1983-10-31
DE3405581A1 (de) 1984-10-18
SE457143B (sv) 1988-12-05
DK72284A (da) 1984-08-17
BE898918A (nl) 1984-08-16
DK165167C (da) 1993-03-01
CH655005A5 (it) 1986-03-27
NL8400488A (nl) 1984-09-17
FR2543827B1 (fr) 1987-06-12
SE8400851L (sv) 1984-08-17
GB2137088A (en) 1984-10-03
IT1170235B (it) 1987-06-03
US4599232A (en) 1986-07-08
NL192778C (nl) 1998-02-03
DE3405581C2 (index.php) 1992-10-22
GB2137088B (en) 1986-02-05

Similar Documents

Publication Publication Date Title
JPH027572B2 (index.php)
US4255449A (en) Method of treating abnormal lipoprote in ratios
US4268524A (en) Method of treating abnormal lipoprotein ratios with acylcarnitine
US6217898B1 (en) Pharmaceutical composition comprising carnitine or alkanoyl L-carnitine, for the prevention and treatment of diseases brought about by lipid metabolism disorders
US5025035A (en) Method of treating depression
CA2229228C (en) Pharmaceutical composition for treating cardiovascular diseases containing 3-(2,2,2-trimethylhydrazinium) propionate and gamma-butyrobetaine
US4382092A (en) Pharmaceutical composition comprising gamma-butyrobetaine for the treatment of syndromes induced by L-carnitine deficiency
HU227042B1 (en) Compostion for the prevention and/or treatment of circulatory disorders, comprising derivatives of l-carnitine and extracts of ginkgo biloba
JP3616116B2 (ja) 心臓血管障害の処置のためのａｃｅ阻害剤を配合するｌ−カルニチンまたはアシル−ｌ−カルニチンを含む医薬組成物
US6653349B1 (en) Composition for the prevention and treatment of kidney dysfunctions and diseases
JPS6296423A (ja) ショック状態の治療のための医薬組成物
US20020002202A1 (en) Use of fumarate salt of L-carnitine or its alkanoyl derivatives in ischaemia
KR100725263B1 (ko) ＨＭＧ-ＣｏＡ 리덕타제 억제제 및 카르니틴을 포함하는 항지질혈성 복합제
JPH03115220A (ja) 非心臓由来の不整脈防止薬
US3150044A (en) Treatment and composition for high blood pressure and palpitation
JPS62286924A (ja) 抗高脂血症剤
JPH02262519A (ja) 糖尿病性神経障害治療剤
JPH0526766B2 (index.php)
HK1005771A1 (en) Use of l-carnitine or acyl l-carnitines and valproate for treating seizure disorders
JPS6232727B2 (index.php)
IE51712B1 (en) Pharmaceutical compositions containing carnitine derivatives

Legal Events

Date Code Title Description
EXPY Cancellation because of completion of term